CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 197 enrolled
Drug / intervention
Zolpidem tartratedrug
Likely dose
Zolpidem tartrate 5mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03774810
NCT03774810Phase 4Completed

Three Approaches to Maintenance Therapy for Chronic Insomnia in Older Adults

University of Pennsylvania·interventional·Posted Dec 13, 2018·Updated May 9, 2025

In Brief

A Phase 4 clinical trial evaluating Zolpidem tartrate for Insomnia and Insomnia Chronic. Completed, enrolled 197 participants across 1 site.

Detailed Summary

The study is a three phase sequential study of the medical treatment of insomnia with zolpidem. All participating subjects will receive one month of standard nightly treatment. If the subject has a positive treatment response they continue in the study and are randomized to one of four conditions: intermittent dosing (3-5 pills week, full dose), or one of three variable dose conditions (nightly pill use where any given pill is a variable dose). Standard treatment will last for 4 weeks. The experimental phase will extend over two periods. The first period will last for 12 weeks. The second period will last for 36 weeks. Both periods include: • Taking a pill 30 minutes prior to bedtime. In one case, this will involve taking 3-5 pills per week. In the remaining condition pills will be taken on each and every night. Depending on the specific group that the subject is assigned to, they will either receive 10mg or 5mg of zolpidem (variable by age and sex) or a variable dose of zolpidem on a nightly basis (range from 0 mg to 10 mg per night). * Completing a sleep diary each day; * Completing 6 to 7 questionnaires each week; * A monthly visit to Penn to return your medication foil packs and to receive a new foil pack with the next month of medication. During Phases 3\&4, the subject will be asked to undergo quarter annual physicals so that we can optimally track their health and wellbeing. The physicals will involve standard vitals measures (e.g., temperature, blood pressure, height and weight, etc.) and, based on the judgement of the research clinician, may involve an EKG and blood and urine chemistries. If the subject does not experience a treatment response or (following a treatment response) experiences a relapse of insomnia, they will not continue in the study but will be given the opportunity to be treated with Cognitive Behavioral Therapy for Insomnia (CBT-I) at no cost. Assessments of the subjects clinical status will be based on your daily sleep diaries and weekly questionnaires.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States

Timeline

Phase 4CompletedFinished
20192020202120222023202420252026
First PostedDec 13, 2018
Enrollment StartApr 15, 2019
Primary CompletionSep 30, 2024
TodayJul 2, 2026
Enrollment to primary: 5.5 yearsPosted 7.6 years ago

Interventions

Zolpidem tartratedrug

Zolpidem Tartrate, 5mg for men older than 60 and women of all ages. 10 mg for men younger than 60.